Showing 2331-2340 of 2652 results for "".
- Centricity Vision Appoints Jim Mazzo to its Board of Directorshttps://modernod.com/news/centricity-vision-appoints-jim-mazzo-to-its-board-of-directors/2478353/Centricity Vision announced that Jim Mazzo has been appointed to the company’s Board of Directors. Mr. Mazzo has over 40 years of experience in the ophthalmology industry. His global reputation for building and running world-class organizations is based on 22 years leading Allergan’s North
- Employers Will Need to Respond Carefully Amid Roller Coaster of Health Costs During COVID-19https://modernod.com/news/employers-will-need-to-respond-carefully-amid-roller-coaster-of-health-costs-during-covid-19/2478345/Employers will likely see drops in year-over-year medical costs in 2020 after large numbers of employees deferred healthcare services due to the COVID-19 pandemic, according to a FierceHealthcare report. Despite the significant drop in the use of healthcare services in 2020, employer heal
- Haag-Streit UK Announces Launch of the MR Q and MR Q Supine Laser Systems in the UKhttps://modernod.com/news/haag-streit-uk-announces-launch-of-the-mr-q-and-mr-q-supine-laser-systems-in-the-uk/2478337/Haag-Streit UK (HS-UK) has announced the launch of the Meridian MR Q and MR Q supine YAG lasers in the UK. The MR Q is a fully-integrated YAG laser, which features the latest technology for posterior capsulotomy, pupillary membranectomy, and iridotomy. The laser boasts outstanding u
- J&J’s COVID-19 Vaccine “Highly Immunogenic” in Early-Stage Testinghttps://modernod.com/news/jjs-covid-19-vaccine-highly-immunogenic-in-early-stage-testing/2478332/Interim phase 1/2a study results for Johnson & Johnson’s experimental COVID-19 vaccine JNJ-78436735 have been published online on the preprint server medRxiv, with researchers saying that a single dose was “well tolerated and highly immunogenic,” and that the findings warran
- Novavax Begins Phase 3 Coronavirus Vaccine Trial in UKhttps://modernod.com/news/novavax-begins-phase-3-coronavirus-vaccine-trial-in-uk/2478330/Novavax said Thursday it has initiated its first phase 3 study to evaluate the efficacy, safety and immunogenicity of its COVID-19 vaccine candidate NVX-CoV2373. The trial, which is being conducted in the UK, is expected to enroll up to 10,000 individuals between the ages of 18 and 84 years, with
- KKR to Acquire 1-800 Contacts from AEA Investorshttps://modernod.com/news/kkr-to-acquire-1-800-contacts-from-aea-investors/2478313/1-800 Contacts, the largest retailer of contact lenses in the US, announced a definitive agreement under which global investment firm KKR will acquire the company from AEA Investors. Financial terms of the transaction were not disclosed. “1-800 Contacts was founded 25 years ago to o
- Johnson & Johnson Starts Phase 3 Study of COVID-19 Vaccine Candidatehttps://modernod.com/news/johnson-johnson-starts-phase-3-study-of-covid-19-vaccine-candidate/2478315/Johnson & Johnson launched a late-stage study of its COVID-19 vaccine candidate JNJ-78436735 following positive interim results from a phase 1/2a trial. The ENSEMBLE study will enroll up to 60,000 volunteers and will evaluate the safety and efficacy of a single vaccine dose versus placebo in
- BioNTech Snaps Up Novartis’ German Site to Expand Coronavirus Vaccine Outputhttps://modernod.com/news/biontech-snaps-up-novartis-german-site-to-expand-coronavirus-vaccine-output/2478296/BioNTech announced that it signed a share purchase agreement to acquire Novartis’ manufacturing facility in Marburg, Germany, a move it says will bolster its COVID-19 vaccine production capacity by up to 750 million doses per year, or over 60 million doses per month. BioNTech, whose Pfizer-
- HelpMeSee Names Saro Jahani As President and CEOhttps://modernod.com/news/helpmesee-names-saro-jahani-as-president-and-ceo/2478266/Nonprofit HelpMeSee announced the appointment of Saro Jahani as President and CEO. He will also join the Board of Directors. Mr. Jahani succeeds Jacob Mohan Thazahathu, who retired after 10 years of service. Mr. Jahani
- Sight Sciences Presents Additional Results of OLYMPIA Study of Signs and Symptoms of Dry Eye Disease Using TearCarehttps://modernod.com/news/sight-sciences-presents-additional-results-of-olympia-study-of-signs-and-symptoms-of-dry-eye-disease-using-tearcare/2478263/Sight Sciences announced further favorable results of a trial evaluating a single treatment of TearCare for the treatment of signs and symptoms of dry eye disease in patients with meibomian gland dysfunction. TearCare is currently marketed for the application of localized heat to the eyelids for